placeholder newsslider


New Technologies for Outcome Measures in Uveal Melanoma

Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma” In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

Algorithm identifies early vascular disease using photos of the eye

Researchers at the University and the University Hospital of Bonn have developed a method that could be used to diagnose atherosclerosis. Using self-learning software, they were able to identify vascular changes in patients with peripheral arterial disease (PAD), often at an early stage.

Open-access publishing fees deter researchers in the global south

Authors in low-income countries rarely published free-to-read papers, even when they qualified for publication-fee waivers.

Ocuphire Pharma completes enrollment in MIRA-3 Pivotal Phase 3 clinical trial for Nyxol in RM

The company completed enrollment ahead of schedule in a second Phase 3 FDA registration trial for Nyxol in RM with top-line results expected by the end of the first quarter.

eSight, Be My Eyes announce sweepstakes winner

The Toronto-based medical eyewear company partnered with the visual assistance community to help empower an Oregon college student with enhanced vision.

What faricimab for DME means for safe, durable treatment over the long term

The results of the YOSEMITE and RHINE phase 3 trials that evaluated the efficacy of faricimab (Vabysmo, Genentech) for treating center-involved diabetic macular edema (DME) compared with aflibercept (Eylea, Regeneron Pharmaceuticals) found that after 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

European Commission appoints the new members of the European Group on Ethics in Science and New Technologies

The European Commission appointed the 15 new members of the new European Group on Ethics in Science and New Technologies (EGE).

The giant plan to track diversity in research journals

Efforts to chart and reduce bias in scholarly publishing will ask authors, reviewers and editors to disclose their race or ethnicity.

The future is now for robot-assisted glaucoma surgery

The first robotic gonio surgery system was developed in the heat of the pandemic in 2020 by the ophthalmology innovation team at New York Eye and Ear Infirmary of Mount Sinai in New York, New York.

Albania completes the Western Balkans association to Horizon Europe

Evis Kushi, Minister of Education and Sports of Albania signed, alongside Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, their Association Agreements to the Horizon Europe programme. This marks an important milestone for closer research and innovation cooperation with the Western Balkans.

High-tech eye drop research targets corneal damage

New research has laid the groundwork for a long-lasting eye drop to treat corneal neovascularisation (CoNV), a condition which affects more than a million people globally each year.

PolyActiva offers results of Phase IIa study of ocular implant

PolyActiva Pty Ltd. announced that the Phase IIa study of its PA5108 ocular implant for the treatment of primary open-angle glaucoma (POAG) met both the study's primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort.

New EU-AU Innovation Agenda to drive sustainable growth and jobs

As part of the Global Gateway Investment Package, the Innovation Agenda has four main objectives: translate innovative capacities and results into tangible outputs; strengthen innovation ecosystems; develop sustainable and mutually beneficial higher education and R&I partnerships; scale-up instruments and programmes that can take forward existing successful initiatives.

Keep science out of Europe’s post-Brexit arguments

Scientific collaboration has become a casualty of Switzerland’s and the United Kingdom’s tussles with the European Union.

EyeBiotech Ltd. raises $65 million to develop new eye disease therapies

The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.